Neoplasms

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Rare Diseases

Lymphoma, Large B-Cell, Diffuse

Lymphoma

Lymphoma, Mantle-Cell

Lymphoma, Follicular

Lymphoma, B-Cell, Marginal Zone

Lymphoma, B-Cell

Lymphoma, Non-Hodgkin

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

B-cell Lymphoma

Diffuse Large B-Cell Lymphoma

Lymphosarcoma

Mantle Cell Lymphoma

Follicular Lymphoma

Marginal Zone Lymphoma

Antineoplastic Agents

Antirheumatic Agents

All Drugs and Chemicals

Cyclophosphamide

Fludarabine

Fludarabine phosphate

Immunosuppressive Agents

Immunologic Factors

Antineoplastic Agents, Alkylating

Alkylating Agents

A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment with SC262

SC262 is an allogeneic CAR -T cell therapy

SC262

Ndidi Onwudiwe

Barbara Martello

Tori Braun

Emily Murakami

Krish Patel, MD

Paul Brunetta, MD

SC262-101 is a Phase 1 study to evaluate SC262 safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.

This is an open-label, single arm, Phase 1, first-in-human (FIH) study to evaluate the safety and tolerability of SC262 administered intravenously (IV) following a standard lymphodepleting chemotherapy regimen of cyclophosphamide and fludarabine in subjects with Non Hodgkin's Lymphoma (NHL) who have received no more than 1 prior CD19-directed Chimeric Antigen Receptor T-Cells (CAR T) cell therapy. This study will be conducted in 2 parts. Dose finding using a 3+3 design in subjects with NHL. Dose expansion to further evaluate safety and efficacy at the recommended phase 2 dose (RP2D) in subjects with Large B-Cell Lymphoma (LBCL).

Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)

A Phase 1 Study Evaluating SC262, a Hypoimmune, Allogeneic CD22-directed CAR T Cell Therapy, in Relapsed and/or Refractory Non-Hodgkin's Lymphoma (VIVID)

Safety and Tolerability: Proportion of subjects experiencing adverse events and dose-limiting toxicities

Preliminary anti-tumor activity: Proportion of subjects with an objective response (including partial response or complete response)

Cellular kinetics related peak (Cmax) in peripheral blood

Cellular kinetics-related parameters evaluated by CAR T cell copy number

Area under the concentration time curve (AUC) in peripheral blood

Incidence of anti-CD19-directed CAR antibodies

Sana Biotechnology

Study Evaluating SC262 in Subjects With r/r B-cell Malignancies (VIVID)

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)	NCT06285422	Non Hodgkin's L... Large B-cell Ly...	SC262	18 Years - 80 Years	Sana Biotechnology
Study Evaluating SC262 in Subjects With r/r B-cell Malignancies (VIVID)	NCT06285422	Non Hodgkin's L... Large B-cell Ly...	SC262	18 Years - 80 Years	Sana Biotechnology

Spots Global Cancer Trial Database for sc262

Every month we try and update this database with for sc262 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for sc262

Every month we try and update this database with for sc262 cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for sc262 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.